Want to see DE:V3V full AI Analyst Report?
VITA 34 (V3V) Price & Analysis
V3V Stock Chart & Stats
- Day’s Range
- EUR 2.78 - EUR 2.79
- 52-Week Range
- EUR 2.58 - EUR 7.15
- Previous Close
- EUR 2.79
- Volume
- 1,201
- Average Volume (3M)
- 1,226
- Market Cap
- EUR 48.46M
- Enterprise Value
- EUR 73.56M
- Total Cash (Recent Filing)
- EUR 12.45M
- Total Debt (Recent Filing)
- EUR 23.03M
- Price to Earnings (P/E)
- ―
- Beta
- 0.15
- Next Earnings
- Nov 30, 2026
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Recurring Biobanking Revenue
The combination of upfront processing income and recurring storage fees gives VITA 34 a more durable revenue base than a purely transactional service. Active contracts can continue generating fees over many years, supporting customer retention, revenue visibility, and operating planning.
Improving Revenue And Margins
Strong TTM revenue growth alongside a gross-margin recovery and positive EBITDA indicates meaningful operating improvement. If maintained, this combination can increase contribution from the existing business, support reinvestment, and improve the path toward sustainable profitability.
Positive Recent Cash Generation
Positive operating and free cash flow provide internally generated funding for ongoing operations and reduce immediate reliance on external capital. This is an important fundamental strength because cash generation has improved even while reported net income remains negative.
Bears Say
Ongoing Net Losses
Persistent operating and net losses weaken earnings quality and limit the company’s ability to build equity through retained profits. Until profitability improves, cash generation may not translate into durable earnings strength, leaving the business more exposed to execution setbacks.
High Leverage And Thin Equity
A sharply higher debt-to-equity ratio and small equity cushion reduce financial flexibility relative to the asset base. This structure can constrain investment choices, increase sensitivity to operating weakness, and make balance-sheet repair dependent on improved results or additional capital.
Volatile Cash-flow Consistency
Recent positive cash flow is encouraging, but the history of negative operating cash flow and sharply negative latest free-cash-flow growth indicates an unstable run-rate. Inconsistent conversion can complicate funding decisions and reduce confidence that current cash generation will persist.
V3V FAQ
What was VITA 34’s price range in the past 12 months?
What is VITA 34’s market cap?
When is VITA 34’s upcoming earnings report date?
How were VITA 34’s earnings last quarter?
Is VITA 34 overvalued?
Does VITA 34 pay dividends?
What is VITA 34’s EPS estimate?
How many shares outstanding does VITA 34 have?
What happened to VITA 34’s price movement after its last earnings report?
Which hedge fund is a major shareholder of VITA 34?
What is the TipRanks Smart Score and how is it calculated?
VITA 34 Stock Smart Score
Company Description
VITA 34
VITA 34 AG is dedicated to the collection, processing, and long-term storage of stem cells derived from umbilical cord blood and tissue. Its operations span Germany, Spain, and global markets. The company actively develops a range of advanced therapeutic solutions, including cell and gene therapies, specialized cell therapeutic procedures, cryopreservation of a patient's own immune cells, and CAR-T cell technology. Furthermore, VITA 34 manufactures advanced therapy medicinal products (ATMPs) based on mesenchymal stem cells for experimental applications by specialized medical institutions. It also preserves stem cells from perinatal tissues and adult body fat, and provides contract manufacturing for pharmaceutical intermediates. Founded in 1997, VITA 34 AG is headquartered in Leipzig, Germany.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Jakub Julian Baran
- Employees
- 723
- Website
- www.famicord.com
- Address
- Perlickstrasse 5, Leipzig, SX, 04103, DE
VITA 34 (V3V) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 5 | 12 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 2 | 0 | 10 |